Compare HNNA & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNNA | INCR |
|---|---|---|
| Founded | 1989 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 78.0M |
| IPO Year | N/A | N/A |
| Metric | HNNA | INCR |
|---|---|---|
| Price | $10.32 | $1.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.9K | ★ 14.4K |
| Earning Date | 12-03-2025 | 10-08-2025 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | ★ 38.04 | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | $35,538,000.00 | ★ $72,158,312.00 |
| Revenue This Year | N/A | $69.54 |
| Revenue Next Year | N/A | $41.75 |
| P/E Ratio | $7.87 | ★ N/A |
| Revenue Growth | ★ 19.88 | N/A |
| 52 Week Low | $8.43 | $1.22 |
| 52 Week High | $13.88 | $1.79 |
| Indicator | HNNA | INCR |
|---|---|---|
| Relative Strength Index (RSI) | 46.88 | 48.70 |
| Support Level | $9.33 | $1.27 |
| Resistance Level | $10.39 | $1.38 |
| Average True Range (ATR) | 0.32 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 61.47 | 69.98 |
Hennessy Advisors Inc is an investment management company, engaged in the managing and marketing of open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, sectors, and specialty, balanced, and fixed income products. It also provides investment advisory services and shareholder services to the Hennessy Funds which include managing the composition of each fund's portfolio, including the purchase, retention, and disposition of portfolio securities as per the Fund's investment objectives, policies, and restrictions; conducting investment research, and monitoring compliance with each fund's investment restrictions and applicable laws and regulations.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.